We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Molecular Probe Lights up Proteases in Tumors

By Biotechdaily staff writers
Posted on 20 Sep 2007
Scientists have developed a molecular probe that sets aglow tumor cells within living animals. More...
This could ultimately be used to improve diagnosis and treatment of cancer and other diseases.

The probe's main ingredient is a molecule that labels active proteases--protein-destroying enzymes--that run amok in cancerous cells. The molecule is normally invisible to the naked eye but it carries a fluorescent tag that lights up when it binds to the protease. The tag beams out near-infrared light that passes through skin and is detectable with a special camera. The use of the technique in mice was described in a study published in the September 9, 2007, online issue of the journal Nature Chemical Biology.

"Nowadays, the detection of cancer, breast cancer for instance, is normally done by mammography, using X-rays--which might actually increase your risk of cancer. We think these probes may ultimately provide a less harmful, noninvasive method of detecting cancer,” said Galia Blum, Ph.D., a postdoctoral scholar in the laboratory of Matthew Bogyo, Ph.D., assistant professor of pathology at the Stanford University School of Medicine (Stanford, CA, USA).

"The next generation of our experiments will apply the probes during surgery,” said Prof. Bogyo, the study's senior author. "It would be nice to ‘paint' it on tissues so you could distinguish between tumor and non-tumor.”

Professor Bogyo, Dr. Blum, and colleagues designed the probe to bind to a subset of a family of proteases called cysteine cathepsins, which are more active in several types of cancer as well as other diseases. Now they altering with the probe's configuration in an effort to create a variant that recognizes the enzymes involved in apoptosis, the process of cell death. This could eventually allow researchers and doctors to visualize response to chemotherapy in tumors.


Related Links:
Stanford University School of Medicine

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Clinical Informatics Platform
CLARION™
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.